Enliven Therapeutics, Inc.

NasdaqGS ELVN

Enliven Therapeutics, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2024: USD -58.00 K

Enliven Therapeutics, Inc. Capital Expenditure is USD -58.00 K for the Trailing 12 Months (TTM) ending September 30, 2024, a 75.42% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Enliven Therapeutics, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -236.00 K, a 58.45% change year over year.
Enliven Therapeutics, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -568.00 K.
Enliven Therapeutics, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -22.00 K.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

NasdaqGS: ELVN

Enliven Therapeutics, Inc.

CEO	Mr. Samuel S. Kintz M.B.A.
IPO Date	March 12, 2020
Location	United States
Headquarters	6200 Lookout Road
Employees	46
Sector	Healthcare
Industries Clinical Trials Biotechnology Pharmaceuticals

Description

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

Key trends

Past 5 years